ClinicalTrials.gg
CompletedNCT00983619Updated May 13, 2020Results posted

A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies

A Phase 1/2 interventional study of MEDI-551 and Rituximab in B-cell Malignancies and Cancer, sponsored by MedImmune LLC. Completed at 21 sites in 5 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2020-05-13.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
136
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The purpose of this study is to determine the maximum tolerated dose of this drug (MEDI-551) in participants with advanced B-cell malignancies. Expansion to occur at maximum tolerated dose (MTD), or if not reached, at optimal biologic dose (OBD).

Read the detailed description

To determine the MTD or OBD of MEDI-551 in participants with relapsed or refractory advanced B-cell malignancies.

02

Conditions studied

  • B-cell Malignancies
  • Cancer

Browse trials for

Keywords

  • Cancer
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 136 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.

Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.

First submitted after MedImmune LLC became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed CLL, DLBCL, FL, or MM;
  • Performance Status >= 70;
  • of >= 12 weeks;
  • Prior radiation therapy provided exposure does not exceed an area of 25% of marrow space
  • Adequate hematological function
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Any available standard known to be life-prolonging or life-saving;
  • No concurrent therapy or therapy within six weeks of first dose of MEDI-551 for treatment of cancer
  • Previous therapy directed against CD19
  • Vaccination (other than experimental cancer vaccine therapy) within 28 days prior to receiving the first dose of MEDI-551;
  • History of other invasive within 5 years except for cervical carcinoma in situ (CIS), non-melanomatous carcinoma of the skin or ductal carcinoma in situ (DCIS) of the breast that have been surgically cured;
  • Active infection requiring treatment
  • stem cell transplantation within 4 months prior to study entry;
  • Allogeneic stem cell transplantation or any other organ transplant;
  • Ongoing >= Grade 2 toxicities from previous cancer therapies unless specifically allowed in the Inclusion/Exclusion criteria.
  • Use of medication other than within 28 days before the first dose of MEDI-551;
  • Use of immunosuppressive medication other than steroids within 28 days before the first dose of MEDI-551 (inhaled and topical corticosteroids are permitted);
  • Documented current central nervous system involvement by leukemia or lymphoma;
  • Pregnancy or lactation;
  • abnormality on .
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    Part A-MEDI-551 0.5 mg/kg

    Participants will receive intravenous (IV) infusion of MEDI 551 0.5 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

    Drug: MEDI-551

  • Experimental
    Part A-MEDI-551 1 mg/kg

    Participants will receive IV infusion of MEDI 551 1 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

    Drug: MEDI-551

  • Experimental
    Part A-MEDI-551 2 mg/kg

    Participants will receive IV infusion of MEDI 551 2 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

    Drug: MEDI-551

  • Experimental
    Part A-MEDI-551 4 mg/kg

    Participants will receive IV infusion of MEDI 551 4 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

    Drug: MEDI-551

  • Experimental
    Part A-MEDI-551 8 mg/kg

    Participants will receive IV infusion of MEDI 551 8 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

    Drug: MEDI-551

  • Experimental
    Part A-MEDI-551 12 mg/kg

    Participants will receive IV infusion of MEDI 551 12 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

    Drug: MEDI-551

  • Experimental
    Part B-MEDI-551 6 mg/kg

    Participants will receive IV infusion of MEDI- 551 6 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

    Drug: MEDI-551

  • Experimental
    Part B-MEDI-551 12 mg/kg

    Participants will receive IV infusion of MEDI- 551 12 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

    Drug: MEDI-551

  • Experimental
    Part B-MEDI-551 24 mg/kg

    Participants will receive IV infusion of MEDI- 551 24 mg/kg weekly for 4 weeks during Cycle 1 (over 2 days on Day 1 and Day 2, and on Days 8, 15, and 22) and thereafter from Cycle 2, on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

    Drug: MEDI-551

  • Experimental
    Part C-MEDI-551 8 mg/kg + rituximab

    Participants will receive IV infusion of MEDI- 551 8 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg will be administered on Day 1 of each 28-day cycle. The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.

    Drug: MEDI-551 · Drug: Rituximab

  • Experimental
    Part C-MEDI-551 12 mg/kg + rituximab

    Participants will receive IV infusion of MEDI- 551 12 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg will be administered on Day 1 of each 28-day cycle. The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.

    Drug: MEDI-551 · Drug: Rituximab

  • Experimental
    Part D-MEDI-551 12 mg/kg

    Participants will receive IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and thereafter Day 1 of 28- day cycles from Cycle 2 onwards. Treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches CR or withdraws consent.

    Drug: MEDI-551

Interventions

  • MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

  • Rituximab will be administered IV on Days 1, 8, 15, and 22 (28- day cycle). The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.

06

What researchers measure

Primary outcomes

  1. Optimal Biologic Dose of MEDI-551 for Part A

    Optimal biologic dose (OBD) was defined as the dose lower than the maximum tolerated dose (MTD), used for dose expansion. The MTD is defined as the highest dose at which less than equal to (\<=) 1 out of 6 participants experience a dose limiting toxicities (DLT) from the time of first administration of MEDI-551 through the first 28-day cycle.

    Time frame: Day 1 to Day 28 of Cycle 1

  2. Highest Protocol-defined Dose for Part B

    Highest protocol-defined dose is dose of MEDI-551 in the absence of exceeding the MTD in participants with relapsed or rituximab-refractory chronic lymphocytic leukemia (defined as those with less than a partial response (PR) or progression within 6 months after completing therapy with rituximab). The MTD is defined as the highest dose at which \<= 1 out of 6 participants experience a DLT from the time of first administration of MEDI-551 through the first 28-day cycle.

    Time frame: Day 1 to Day 28 of Cycle 1

  3. Highest Protocol-defined Dose for Part C

    Highest protocol-defined dose is the dose of MEDI-551 in combination with rituximab at the MTD or the highest protocol-defined dose in the absence of exceeding the MTD in participants with aggressive lymphomas. The MTD is defined as the highest dose at which \<= 1 out of 6 participants experience a DLT from the time of first administration of MEDI-551 through the first 28-day cycle.

    Time frame: Day 1 to Day 28 of Cycle 1

  4. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) for Part A, Part B, and Part C

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

    Time frame: Day 1 through 90-Day Post Last Dose (Approximately 9 years)

  5. Number of Participants With Dose Limiting Toxicities of MEDI-551 in Part A, Part B, and Part C

    A dose limiting toxicities (DLT) for arm A, B, and C was defined as MEDI-551 (or rituximab for Arm C) treatment-related AE of any toxicity grade that led to an inability to receive a full cycle of MEDI-551 (or rituximab for Arm C) or any Grade 3 or higher toxicity (except Grade 3 fever, transient Grade 3 rigors or chills, Grade 3 tumor lysis syndrome, any Grade 3 or 4 electrolyte alteration, any Grade 3 liver function test elevation,\>= Grade 3 or 4 lymphopenia or leukopenia, \<= Grade 4 neutropenia, \<= Grade 4 thrombocytopenia, \<= Grade 4 anemia, and Grade 3 infusion-related reaction and infusion reaction), during DLT evaluable period.

    Time frame: Day 1 to Day 28 of Cycle 1

  6. Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs in Part A, Part B, and Part C

    Number of participants with clinical laboratory abnormalities reported as TEAEs are reported. Clinical laboratory abnormalities are defined as any abnormal findings in analysis of serum chemistry, hematology, and urine.

    Time frame: Day 1 through 90-Day Post Last Dose (Approximately 9 years)

  7. Number of Participants With Abnormal Vital Signs Reported as TEAEs in Part A, Part B, and Part C

    Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal findings in the vital signs parameters (temperature, blood pressure, pulse rate, respiratory rate, and pulse oximetry).

    Time frame: Day 1 through 90-Day Post Last Dose (Approximately 9 years)

  8. Number of Participants With Abnormal Electrocardiograms Reported as TEAEs in Part A, Part B, and Part C

    Number of participants with abnormal electrocardiograms (ECGs) reported as TEAEs are reported. Abnormal ECGs are defined as any abnormal findings in heart rate, RR interval, PR interval, QRS, axis, and QT intervals from the primary lead of the digital 12-lead ECG.

    Time frame: Day 1 through 90-Day Post Last Dose (Approximately 9 years)

  9. Percentage of Participants With Complete Response for Part B, Part C, and Part D

    Complete response (CR) is defined as disappearance of all evidence of disease according to International Working Group criteria (IWG). For nodal masses; fluorodeoxyglucose (FDG)-avid or polyethylene terephthalate (PET) positive prior to therapy; mass of any size permitted if PET negative .Variably FDG-avid or PET negative; regression to normal size on computed tomography (CT). For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry (IHC) was negative.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  10. Percentage of Participants With Partial Response for Part B, Part C, and Part D

    The PR is defined as regression of measurable disease and no new sites according to IWG criteria. Nodal masses: \>= 50% decrease in sum of the product diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) FDG-avid or PET negative; regression on CT. Spleen and liver: \>= 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone marrow: irrelevant if positive prior to therapy.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  11. Duration of Complete Response for Part B, Part C, and Part D

    Duration of CR is from the first documentation of a CR to the time of progressive disease/relapse according to IWG criteria. The CR is disappearance of all evidence of disease according to IWG criteria. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. Variably FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. Kaplan-Meier method was used to evaluate duration of CR.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  12. Percentage of Participants With Objective Response Rate for Part B, Part C, and Part D

    Objective response rate (ORR) is proportion of participants with CR or partial response (PR) as per IWG criteria. CR is disappearance of all evidence of disease. Nodal masses; FDG-avid/PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. Spleen; not palpable, nodules disappeared. Bone marrow; infiltrate cleared on repeat biopsy; if unknown by morphology, IHC was negative. PR is regression of measurable disease and no new sites. Nodal masses: \>= 50% decrease in sum of the product diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) FDG-avid or PET negative; regression on CT. Spleen and liver: \>= 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone marrow: irrelevant if positive prior to therapy.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  13. Duration of Objective Response for Part B, Part C, and Part D

    Duration of objective response (DOR) is the first documentation of objective response to the first documented progressive disease (PD) or relapse according to IWG criteria. PD is defined as any new lesion or increase by \>=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion(s) \> 1.5 cm in any axis, \>= 50% increase in SPD of more than one node, or \>= 50% increase in longest diameter of a previously identified node \> 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: \> 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate DOR.

    Time frame: Cycle 1 Day 1, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  14. Percentage of Participants With Disease Control Rate for Part B, Part C, and Part D

    Disease control includes CR, PR, or stable disease (SD) for at least 8 weeks according to IWG criteria. The CR is disappearance of all evidence of disease. Nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. Spleen; not palpable, nodules disappeared. Bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. PR is regression of measurable disease and no new sites. Nodal masses: \>= 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) Variably FDG-avid or PET negative; regression on CT. Spleen and liver: \>= 50% decrease in SPD of nodules; no increase in size of liver or spleen. For bone marrow: irrelevant if positive prior to therapy. SD is failure to attain CR/PR or PD.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  15. Duration of Disease Control for Part B, Part C, and Part D

    Duration of disease control is defined as the time period from start of MEDI-551 administration to the event of PD/relapse. PD is defined as any new lesion or increase by \>=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion(s) \> 1.5 cm in any axis, \>= 50% increase in SPD of more than one node, or \>= 50% increase in longest diameter of a previously identified node \> 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: \> 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate duration of disease control.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  16. Time to Response for Part B, Part C, and Part D

    Time to response (TTR) is measured from the start of MEDI-551 administration to the first documentation of response (CR or PR) and assessed in participants who have achieved objective response. Kaplan-Meier method was used to evaluate TTR.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  17. Progression Free Survival for Part B, Part C, and Part D

    Progression-free survival (PFS) is measured from the start of MEDI-551 treatment until the first documentation of disease progression, relapse or death, whichever occurs first. The PFS was censored on the date of last disease assessment for participants who have no documented PD/relapse or death prior to data cutoff, dropout, or the initiation of alternative anticancer therapy. Kaplan-Meier method was used to evaluate PFS.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  18. Overall Survival for Part B, Part C, and Part D

    Overall survival (OS) is measured from the start of MEDI-551 treatment until death. For participants who are alive at the end of study or lost to follow-up, OS will be censored on the last date when participants were known to be alive. Kaplan-Meier method was used to evaluate OS.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) for Part D

    An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

    Time frame: Day 1 through 90-Day Post Last Dose (Approximately 9 years)

  2. Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs in Part D

    Number of participants with clinical laboratory abnormalities reported as TEAEs are reported. Clinical laboratory abnormalities are defined as any abnormal findings in analysis of serum chemistry, hematology, and urine.

    Time frame: Day 1 through 90-Day Post Last Dose (Approximately 9 years)

  3. Number of Participants With Abnormal Vital Signs Reported as TEAEs in Part D

    Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal findings in the vital signs parameters (temperature, blood pressure, pulse rate, respiratory rate, and pulse oximetry).

    Time frame: Day 1 through 90-Day Post Last Dose (Approximately 9 years)

  4. Number of Participants With Abnormal Electrocardiograms Reported as TEAEs in Part D

    Number of participants with abnormal ECGs reported as TEAEs are reported. Abnormal ECGs are defined as any abnormal findings in heart rate, RR interval, PR interval, QRS, axis, and QT intervals from the primary lead of the digital 12-lead ECG.

    Time frame: Day 1 through 90-Day Post Last Dose (Approximately 9 years)

  5. Percentage of Participants With Complete Response for Part A

    The CR is defined as disappearance of all evidence of disease according to IWG criteria. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative .Variably FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  6. Percentage of Participants With Partial Response for Part A

    The PR is defined as regression of measurable disease and no new sites according to IWG criteria. Nodal masses: \>= 50% decrease in sum of the product diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) FDG-avid or PET negative; regression on CT. Spleen and liver: \>= 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone marrow: irrelevant if positive prior to therapy.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  7. Duration of Complete Response for Part A

    Duration of CR is from the first documentation of a CR to the time of progressive disease/relapse according to IWG criteria. The CR is disappearance of all evidence of disease. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. Variably FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. Kaplan-Meier method was used to evaluate duration of CR.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  8. Percentage of Participants With Objective Response Rate for Part A

    The ORR is defined as proportion of participants with CR or PR according to IWG criteria. CR is disappearance of all evidence of disease. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if unknown by morphology, IHC was negative. PR is regression of measurable disease and no new sites. For nodal masses: \>= 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) FDG-avid or PET negative; regression on CT. For spleen and liver: \>= 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. For bone marrow: irrelevant if positive prior to therapy.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  9. Duration of Objective Response for Part A

    The DOR is the first documentation of objective response to the first documented PD or relapse according to IWG criteria. PD is defined as any new lesion or increase by \>=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion(s) \> 1.5 cm in any axis, \>= 50% increase in SPD of more than one node, or \>= 50% increase in longest diameter of a previously identified node \> 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: \> 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate DOR.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  10. Percentage of Participants With Disease Control Rate for Part A

    Disease control includes CR, PR, or SD for at least 8 weeks according to IWG criteria. The CR is disappearance of all evidence of disease. For nodal masses; FDG -avid or PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. PR is regression of measurable disease and no new sites. For nodal masses: \>= 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) Variably FDG-avid or PET negative; regression on CT. For spleen and liver: \>= 50% decrease in SPD of nodules; no increase in size of liver or spleen. For bone marrow: irrelevant if positive prior to therapy. SD is failure to attain CR/PR or PD.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  11. Duration of Disease Control for Part A

    Duration of disease control is defined as the time period from start of MEDI-551 administration to the event of PD/relapse according to IWG criteria. PD is defined as any new lesion or increase by \>=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion(s) \> 1.5 cm in any axis, \>= 50% increase in SPD of more than one node, or \>= 50% increase in longest diameter of a previously identified node \> 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: \> 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate duration of disease control.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  12. Time to Response for Part A

    The TTR is measured from the start of MEDI-551 administration to the first documentation of response (CR or PR) and assessed in participants who have achieved objective response. Kaplan-Meier method was used to evaluate TTR.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  13. Progression Free Survival for Part A

    The PFS is measured from the start of MEDI-551 treatment until the first documentation of disease progression, relapse or death, whichever occurs first. Kaplan-Meier method was used to evaluate PFS. The PFS was censored on the date of last disease assessment for participants who have no documented PD/relapse or death prior to data cutoff, dropout, or the initiation of alternative anticancer therapy.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  14. Overall Survival for Part A

    The OS is measured from the start of MEDI-551 treatment until death. For participants who are alive at the end of study or lost to follow-up, OS will be censored on the last date when participants were known to be alive. Kaplan-Meier method was used to evaluate OS.

    Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)

  15. Trough Serum Concentration of MEDI-551 by Treatment Cycle

    Trough serum concentration (Ctrough) is defined as lowest concentration reached by a drug before the next dose is administered. The Ctrough concentration of MEDI-551 by treatment cycle is reported.

    Time frame: For Part A: C1D1 of each cycles; For Part B: C1D1 of each cycle + C1D8, C1D15, and C1D22; For Part C: C1D2, C1D8, then Day 1 of each cycle until Cycle 10;For Part D: C1D1, C1D8, then Day 1 of each cycle until Cycle 10

  16. Peak Serum Concentration of MEDI-551 by Treatment Cycle

    Peak serum concentration is concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and before the administration of a second dose.

    Time frame: For Part A: C1D1 of each cycles; For Part B: C1D1 of each cycle + C1D8, C1D15, and C1D22; For Part C: C1D2, C1D8, then Day 1 of each cycle until Cycle 10;For Part D: C1D1, C1D8, then Day 1 of each cycle until Cycle 10

  17. Area Under the Concentration Curve at Steady State (AUCss) of MEDI-551

    Area under the concentration-time curve at steady state (Css, AUC) of MEDI-551 is reported.

    Time frame: Part A:Cycle(C)1 Day(D)1 (Pre & post dose [PPD] 2,6,24,48 hrs PD); PPD once a week in 4 weeks C till C71; Part B:C1 (D1,D8,D15,D22),PPD of D1 of each C till C28; Part C & D:PPD of C1 (D2,D8), predose D15 and 22, PPD of D1 of each C till C24

  18. Apparent Clearance of MEDI-551

    Apparent clearance of MEDI-551 is reported.

    Time frame: Part A:Cycle(C)1 Day(D)1 (Pre & post dose [PPD] 2,6,24,48 hrs PD); PPD once a week in 4 weeks C till C71; Part B:C1 (D1,D8,D15,D22),PPD of D1 of each C till C28; Part C & D:PPD of C1 (D2,D8), predose D15 and 22, PPD of D1 of each C till C24

  19. Volume of Distribution of MEDI-551

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Central volume of distribution (Vd1) is defined as hypothetical volume into which a drug initially distributes upon administration and peripheral volume of distribution (Vd2) is defined as the sum of all tissue spaces outside the central compartment.

    Time frame: Part A:Cycle(C)1 Day(D)1 (Pre & post dose [PPD] 2,6,24,48 hrs PD); PPD once a week in 4 weeks C till C71; Part B:C1 (D1,D8,D15,D22),PPD of D1 of each C till C28; Part C & D:PPD of C1 (D2,D8), predose D15 and 22, PPD of D1 of each C till C24

  20. Terminal Half-life (t1/2) of MEDI-551

    Terminal half-life is the time required for the plasma concentration of MEDI-551 to fall by 50% during the terminal phase.

    Time frame: Part A:Cycle(C)1 Day(D)1 (Pre & post dose [PPD] 2,6,24,48 hrs PD); PPD once a week in 4 weeks C till C71; Part B:C1 (D1,D8,D15,D22),PPD of D1 of each C till C28; Part C & D:PPD of C1 (D2,D8), predose D15 and 22, PPD of D1 of each C till C24

  21. Number of Participants With Positive Anti-drug Antibodies (ADA) Titer to MEDI-551

    Number of participants with positive Anti-drug antibodies (ADA) titer to MEDI-551 is reported.

    Time frame: Part A:C1D1; Part B: C1D1; Part C: C1D1; Part D: C1D1; End of treatment (EOT); 90 Days post last dose (approximately 9 years)

  22. B-cell Concentration in Serum

    B-cell Concentration in serum is reported.

    Time frame: Part A:C1D1 of each cycles; Part B: C1D1 of each cycle + C1D8, C1D15, and C1D22; Part C: C1D2, C1D8, then Day 1 of each cycle until Cycle 10; Part D: C1D1, C1D8, Day 1 of each cycle until Cycle 10; EOT;90 Days post last dose (approximately 9 years)

  23. Immunoglobulin (Ig) Concentration in Serum

    Immunoglobin (Ig) concentration in serum is reported.

    Time frame: Part A:C1D1 of each cycles; EOT;90 Days post last dose (approximately 9 years)

07

Results

Posted May 13, 2020

Participant flow

Participant flow — Overall Study
MilestonePart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
Started343637633131714
Completed000109010063
Not completed343536732131111
Withdrew: Lost to follow-up010002000002
Withdrew: Withdrawal by subject2113123000011
Withdrew: Death0221230101298
Withdrew: Other1001012220110

Outcome measures

PrimaryOptimal Biologic Dose of MEDI-551 for Part A

Optimal biologic dose (OBD) was defined as the dose lower than the maximum tolerated dose (MTD), used for dose expansion. The MTD is defined as the highest dose at which less than equal to (\<=) 1 out of 6 participants experience a dose limiting toxicities (DLT) from the time of first administration of MEDI-551 through the first 28-day cycle.

Time frame:
Day 1 to Day 28 of Cycle 1
Reported as:
Number · mg/Kg
Optimal Biologic Dose of MEDI-551 for Part A
mg/KgPart A-MEDI-551 Part A
Optimal Biologic Dose of MEDI-551 for Part A12
PrimaryHighest Protocol-defined Dose for Part B

Highest protocol-defined dose is dose of MEDI-551 in the absence of exceeding the MTD in participants with relapsed or rituximab-refractory chronic lymphocytic leukemia (defined as those with less than a partial response (PR) or progression within 6 months after completing therapy with rituximab). The MTD is defined as the highest dose at which \<= 1 out of 6 participants experience a DLT from the time of first administration of MEDI-551 through the first 28-day cycle.

Time frame:
Day 1 to Day 28 of Cycle 1
Reported as:
Number · mg/Kg
Highest Protocol-defined Dose for Part B
mg/KgPart B-MEDI-551
Highest Protocol-defined Dose for Part B24
PrimaryHighest Protocol-defined Dose for Part C

Highest protocol-defined dose is the dose of MEDI-551 in combination with rituximab at the MTD or the highest protocol-defined dose in the absence of exceeding the MTD in participants with aggressive lymphomas. The MTD is defined as the highest dose at which \<= 1 out of 6 participants experience a DLT from the time of first administration of MEDI-551 through the first 28-day cycle.

Time frame:
Day 1 to Day 28 of Cycle 1
Reported as:
Number · mg/kg
Highest Protocol-defined Dose for Part C
mg/kgPart C-MEDI-551 + Rituximab
Highest Protocol-defined Dose for Part C12
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) for Part A, Part B, and Part C

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

Time frame:
Day 1 through 90-Day Post Last Dose (Approximately 9 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) for Part A, Part B, and Part C
ParticipantsPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + Rituximab
TEAEs3436376331317
TESAEs112112312119
PrimaryNumber of Participants With Dose Limiting Toxicities of MEDI-551 in Part A, Part B, and Part C

A dose limiting toxicities (DLT) for arm A, B, and C was defined as MEDI-551 (or rituximab for Arm C) treatment-related AE of any toxicity grade that led to an inability to receive a full cycle of MEDI-551 (or rituximab for Arm C) or any Grade 3 or higher toxicity (except Grade 3 fever, transient Grade 3 rigors or chills, Grade 3 tumor lysis syndrome, any Grade 3 or 4 electrolyte alteration, any Grade 3 liver function test elevation,\>= Grade 3 or 4 lymphopenia or leukopenia, \<= Grade 4 neutropenia, \<= Grade 4 thrombocytopenia, \<= Grade 4 anemia, and Grade 3 infusion-related reaction and infusion reaction), during DLT evaluable period.

Time frame:
Day 1 to Day 28 of Cycle 1
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities of MEDI-551 in Part A, Part B, and Part C
ParticipantsPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + Rituximab
Number of Participants With Dose Limiting Toxicities of MEDI-551 in Part A, Part B, and Part C00000100000
PrimaryNumber of Participants With Clinical Laboratory Abnormalities Reported as TEAEs in Part A, Part B, and Part C

Number of participants with clinical laboratory abnormalities reported as TEAEs are reported. Clinical laboratory abnormalities are defined as any abnormal findings in analysis of serum chemistry, hematology, and urine.

Time frame:
Day 1 through 90-Day Post Last Dose (Approximately 9 years)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs in Part A, Part B, and Part C
ParticipantsPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + Rituximab
Anemia02001601104
Blood fibrinogen decreased01000001000
Blood fibrinogen increased01000101000
Febrile neutropenia00000201001
Hematocrit decreased01000000000
Hemoglobin increased00000100000
Leukopenia00000101000
Lymphocyte count decreased01000000102
Lymphopenia00000201000
Myelocytosis00000100000
Neutropenia000111411012
Neutrophil count abnormal01000000000
Neutrophil count decreased11010501102
Platelet count decreased00000201101
Red blood cell count decreased01000000000
Reticulocytosis00000100000
Thrombocytopenia01030601002
White blood cell count decreased00011302102
Hypergammaglobulinemia00000010000
Activated PTT prolonged00000000001
Leukocytosis00000000001
Alanine aminotransferase increased01000300101
Aspartate aminotransferase increased01000400101
Blood alkaline phosphatase increased00000100102
Blood chloride decreased01000000000
Blood creatinine increased00100101102
Blood glucose decreased00000100000
Blood glucose increased00000100000
Blood lactate dehydrogenase increased00000200101
Blood potassium decreased00000100000
Blood urea increased01000000000
Blood uric acid increased00000100000
Gamma-glutamyl transferase increased00000300000
Hyperbilirubinemia00010000001
Hypercalcemia00000400001
Hyperglycemia00010100002
Hyperkalemia02000000000
Hyperuricemia11000200101
Hypocalcemia02000001102
Hypoglycemia01000100001
Hypokalemia00000101001
Hypomagnesemia00000201001
Hyponatremia01010000002
Protein total decreased00010001000
Blood albumin decreased00000001000
Hypernatremia00000000102
Hypoalbuminemia00000000102
Haematuria00000200002
Dysuria00000100002
Pollakiuria00000200000
Hemoglobinuria00000200000
Hydronephrosis00000000002
Urinary incontinence00000100001
PrimaryNumber of Participants With Abnormal Vital Signs Reported as TEAEs in Part A, Part B, and Part C

Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal findings in the vital signs parameters (temperature, blood pressure, pulse rate, respiratory rate, and pulse oximetry).

Time frame:
Day 1 through 90-Day Post Last Dose (Approximately 9 years)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Vital Signs Reported as TEAEs in Part A, Part B, and Part C
ParticipantsPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + Rituximab
Bradycardia10000000000
Chills00010501001
Dyspnea011101002104
Hypertension21000802002
Hypotension13100400102
Orthostatic hypotension00100000000
Palpitations00000100001
Pyrexia001201611003
Systolic hypertension00000200000
Tachycardia00000610001
PrimaryNumber of Participants With Abnormal Electrocardiograms Reported as TEAEs in Part A, Part B, and Part C

Number of participants with abnormal electrocardiograms (ECGs) reported as TEAEs are reported. Abnormal ECGs are defined as any abnormal findings in heart rate, RR interval, PR interval, QRS, axis, and QT intervals from the primary lead of the digital 12-lead ECG.

Time frame:
Day 1 through 90-Day Post Last Dose (Approximately 9 years)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiograms Reported as TEAEs in Part A, Part B, and Part C
ParticipantsPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + Rituximab
Sinus bradycardia01000000000
Atrial fibrillation00000301000
Mitral valve incompetence00000100010
Supraventricular extrasystoles00000100000
Tricuspid valve incompetence00000100000
ECG QT prolonged00100100001
Atrial flutter00000001000
Atrial tachycardia00000001000
Supraventricular tachycardia00000001001
PrimaryPercentage of Participants With Complete Response for Part B, Part C, and Part D

Complete response (CR) is defined as disappearance of all evidence of disease according to International Working Group criteria (IWG). For nodal masses; fluorodeoxyglucose (FDG)-avid or polyethylene terephthalate (PET) positive prior to therapy; mass of any size permitted if PET negative .Variably FDG-avid or PET negative; regression to normal size on computed tomography (CT). For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry (IHC) was negative.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Complete Response for Part B, Part C, and Part D
Percentage of ParticipantsPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
Percentage of Participants With Complete Response for Part B, Part C, and Part D33.3 (0.8 to 90.6)0 (0.0 to 70.8)—33.3 (0.8 to 90.6)18.8 (4.0 to 45.6)0 (0.0 to 24.7)
PrimaryPercentage of Participants With Partial Response for Part B, Part C, and Part D

The PR is defined as regression of measurable disease and no new sites according to IWG criteria. Nodal masses: \>= 50% decrease in sum of the product diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) FDG-avid or PET negative; regression on CT. Spleen and liver: \>= 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone marrow: irrelevant if positive prior to therapy.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Partial Response for Part B, Part C, and Part D
Percentage of ParticipantsPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
Percentage of Participants With Partial Response for Part B, Part C, and Part D33.333.3—33.325.023.1
PrimaryDuration of Complete Response for Part B, Part C, and Part D

Duration of CR is from the first documentation of a CR to the time of progressive disease/relapse according to IWG criteria. The CR is disappearance of all evidence of disease according to IWG criteria. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. Variably FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. Kaplan-Meier method was used to evaluate duration of CR.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Median · Months
Duration of Complete Response for Part B, Part C, and Part D
MonthsPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
Duration of Complete Response for Part B, Part C, and Part DNA (5.6 to 5.6)——NA (0.3 to 0.3)NA (20.0 to 38.4)—
PrimaryPercentage of Participants With Objective Response Rate for Part B, Part C, and Part D

Objective response rate (ORR) is proportion of participants with CR or partial response (PR) as per IWG criteria. CR is disappearance of all evidence of disease. Nodal masses; FDG-avid/PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. Spleen; not palpable, nodules disappeared. Bone marrow; infiltrate cleared on repeat biopsy; if unknown by morphology, IHC was negative. PR is regression of measurable disease and no new sites. Nodal masses: \>= 50% decrease in sum of the product diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) FDG-avid or PET negative; regression on CT. Spleen and liver: \>= 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone marrow: irrelevant if positive prior to therapy.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response Rate for Part B, Part C, and Part D
Percentage of participantsPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
Percentage of Participants With Objective Response Rate for Part B, Part C, and Part D66.7 (9.4 to 99.2)33.3 (0.8 to 90.6)—66.7 (9.4 to 99.2)43.8 (19.8 to 70.1)23.1 (5.0 to 53.8)
PrimaryDuration of Objective Response for Part B, Part C, and Part D

Duration of objective response (DOR) is the first documentation of objective response to the first documented progressive disease (PD) or relapse according to IWG criteria. PD is defined as any new lesion or increase by \>=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion(s) \> 1.5 cm in any axis, \>= 50% increase in SPD of more than one node, or \>= 50% increase in longest diameter of a previously identified node \> 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: \> 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate DOR.

Time frame:
Cycle 1 Day 1, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Median · Months
Duration of Objective Response for Part B, Part C, and Part D
MonthsPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
Duration of Objective Response for Part B, Part C, and Part DNA (38.9 to 47.2)27.5 (27.5 to 27.5)—3.7 (2.4 to 3.7)NA (1.0 to 44.7)3.7 (1.9 to 27.2)
PrimaryPercentage of Participants With Disease Control Rate for Part B, Part C, and Part D

Disease control includes CR, PR, or stable disease (SD) for at least 8 weeks according to IWG criteria. The CR is disappearance of all evidence of disease. Nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. Spleen; not palpable, nodules disappeared. Bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. PR is regression of measurable disease and no new sites. Nodal masses: \>= 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) Variably FDG-avid or PET negative; regression on CT. Spleen and liver: \>= 50% decrease in SPD of nodules; no increase in size of liver or spleen. For bone marrow: irrelevant if positive prior to therapy. SD is failure to attain CR/PR or PD.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Control Rate for Part B, Part C, and Part D
Percentage of participantsPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
Percentage of Participants With Disease Control Rate for Part B, Part C, and Part D100 (29.2 to 100)100 (29.2 to 100)—100 (29.2 to 100)68.8 (41.3 to 89.0)46.2 (19.2 to 74.9)
PrimaryDuration of Disease Control for Part B, Part C, and Part D

Duration of disease control is defined as the time period from start of MEDI-551 administration to the event of PD/relapse. PD is defined as any new lesion or increase by \>=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion(s) \> 1.5 cm in any axis, \>= 50% increase in SPD of more than one node, or \>= 50% increase in longest diameter of a previously identified node \> 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: \> 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate duration of disease control.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Median · Months
Duration of Disease Control for Part B, Part C, and Part D
MonthsPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
Duration of Disease Control for Part B, Part C, and Part DNA (9.7 to 50.9)29.8 (22.6 to 39.5)—5.5 (4.2 to 5.5)14.6 (1.7 to 46.5)3.8 (3.5 to 29.0)
PrimaryTime to Response for Part B, Part C, and Part D

Time to response (TTR) is measured from the start of MEDI-551 administration to the first documentation of response (CR or PR) and assessed in participants who have achieved objective response. Kaplan-Meier method was used to evaluate TTR.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Median · Months
Time to Response for Part B, Part C, and Part D
MonthsPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
Time to Response for Part B, Part C, and Part D6.5 (3.7 to 9.2)12.0 (12.0 to 12.0)—1.8 (1.7 to 1.8)2.0 (1.7 to 17.3)1.8 (1.6 to 1.9)
PrimaryProgression Free Survival for Part B, Part C, and Part D

Progression-free survival (PFS) is measured from the start of MEDI-551 treatment until the first documentation of disease progression, relapse or death, whichever occurs first. The PFS was censored on the date of last disease assessment for participants who have no documented PD/relapse or death prior to data cutoff, dropout, or the initiation of alternative anticancer therapy. Kaplan-Meier method was used to evaluate PFS.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Median · Months
Progression Free Survival for Part B, Part C, and Part D
MonthsPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
Progression Free Survival for Part B, Part C, and Part DNA (9.7 to 50.9)29.8 (22.6 to 39.5)—5.5 (4.2 to 5.5)3.5 (0.7 to 46.5)2.0 (0.7 to 29.0)
PrimaryOverall Survival for Part B, Part C, and Part D

Overall survival (OS) is measured from the start of MEDI-551 treatment until death. For participants who are alive at the end of study or lost to follow-up, OS will be censored on the last date when participants were known to be alive. Kaplan-Meier method was used to evaluate OS.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Median · Months
Overall Survival for Part B, Part C, and Part D
MonthsPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
Overall Survival for Part B, Part C, and Part DNA (19.4 to 53.8)NA (37.6 to 41.9)—25.0 (18.3 to 45.4)33.4 (0.9 to 51.3)17.9 (1.2 to 38.9)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) for Part D

An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

Time frame:
Day 1 through 90-Day Post Last Dose (Approximately 9 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) for Part D
ParticipantsPart D-MEDI-551 12 mg/kg
TEAEs14
TESAEs5
SecondaryNumber of Participants With Clinical Laboratory Abnormalities Reported as TEAEs in Part D

Number of participants with clinical laboratory abnormalities reported as TEAEs are reported. Clinical laboratory abnormalities are defined as any abnormal findings in analysis of serum chemistry, hematology, and urine.

Time frame:
Day 1 through 90-Day Post Last Dose (Approximately 9 years)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs in Part D
ParticipantsPart D-MEDI-551 12 mg/kg
Anemia2
Febrile neutropenia1
Lymphocyte count decreased3
Neutropenia1
Neutrophil count decreased4
Platelet count decreased1
Polycythemia1
Thrombocytopenia2
White blood cell count decreased3
Blood ALP increased1
Blood bilirubin increased1
Blood LDH increased1
Blood potassium decreased1
Hypercalcemia1
Hyperglycemia2
Hyperuricemia2
Hypocalcemia1
Hypokalemia2
Pollakiuria1
Urinary incontinence1
SecondaryNumber of Participants With Abnormal Vital Signs Reported as TEAEs in Part D

Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal findings in the vital signs parameters (temperature, blood pressure, pulse rate, respiratory rate, and pulse oximetry).

Time frame:
Day 1 through 90-Day Post Last Dose (Approximately 9 years)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Vital Signs Reported as TEAEs in Part D
ParticipantsPart D-MEDI-551 12 mg/kg
Chills2
Dyspnea1
Hypertension1
Hypotension1
Palpitations1
Pyrexia2
Tachycardia1
SecondaryNumber of Participants With Abnormal Electrocardiograms Reported as TEAEs in Part D

Number of participants with abnormal ECGs reported as TEAEs are reported. Abnormal ECGs are defined as any abnormal findings in heart rate, RR interval, PR interval, QRS, axis, and QT intervals from the primary lead of the digital 12-lead ECG.

Time frame:
Day 1 through 90-Day Post Last Dose (Approximately 9 years)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiograms Reported as TEAEs in Part D
ParticipantsPart D-MEDI-551 12 mg/kg
Number of Participants With Abnormal Electrocardiograms Reported as TEAEs in Part D1
SecondaryPercentage of Participants With Complete Response for Part A

The CR is defined as disappearance of all evidence of disease according to IWG criteria. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative .Variably FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Complete Response for Part A
Percentage of ParticipantsPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kg
Percentage of Participants With Complete Response for Part A33.3 (0.8 to 90.6)0 (0.0 to 60.2)0 (0.0 to 70.8)20.0 (0.5 to 71.6)0 (0.0 to 70.8)12.5 (5.9 to 22.4)
SecondaryPercentage of Participants With Partial Response for Part A

The PR is defined as regression of measurable disease and no new sites according to IWG criteria. Nodal masses: \>= 50% decrease in sum of the product diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) FDG-avid or PET negative; regression on CT. Spleen and liver: \>= 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone marrow: irrelevant if positive prior to therapy.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Partial Response for Part A
Percentage of ParticipantsPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kg
Percentage of Participants With Partial Response for Part A33.300033.315.3
SecondaryDuration of Complete Response for Part A

Duration of CR is from the first documentation of a CR to the time of progressive disease/relapse according to IWG criteria. The CR is disappearance of all evidence of disease. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. Variably FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. Kaplan-Meier method was used to evaluate duration of CR.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Median · Months
Duration of Complete Response for Part A
MonthsPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kg
Duration of Complete Response for Part A7.1 (7.1 to 7.1)——14.9 (14.9 to 14.9)—14.3 (1.9 to 31.8)
SecondaryPercentage of Participants With Objective Response Rate for Part A

The ORR is defined as proportion of participants with CR or PR according to IWG criteria. CR is disappearance of all evidence of disease. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if unknown by morphology, IHC was negative. PR is regression of measurable disease and no new sites. For nodal masses: \>= 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) FDG-avid or PET negative; regression on CT. For spleen and liver: \>= 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. For bone marrow: irrelevant if positive prior to therapy.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response Rate for Part A
Percentage of participantsPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kg
Percentage of Participants With Objective Response Rate for Part A66.7 (9.4 to 99.2)0 (0.0 to 60.2)0 (0.0 to 70.8)20.0 (0.5 to 71.6)33.3 (0.8 to 90.6)27.8 (17.9 to 39.6)
SecondaryDuration of Objective Response for Part A

The DOR is the first documentation of objective response to the first documented PD or relapse according to IWG criteria. PD is defined as any new lesion or increase by \>=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion(s) \> 1.5 cm in any axis, \>= 50% increase in SPD of more than one node, or \>= 50% increase in longest diameter of a previously identified node \> 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: \> 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate DOR.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Median · Months
Duration of Objective Response for Part A
MonthsPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kg
Duration of Objective Response for Part A8.8 (7.4 to 8.8)——15.0 (15.0 to 15.0)3.0 (3.0 to 3.0)19.8 (0.0 to 41.9)
SecondaryPercentage of Participants With Disease Control Rate for Part A

Disease control includes CR, PR, or SD for at least 8 weeks according to IWG criteria. The CR is disappearance of all evidence of disease. For nodal masses; FDG -avid or PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. PR is regression of measurable disease and no new sites. For nodal masses: \>= 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) Variably FDG-avid or PET negative; regression on CT. For spleen and liver: \>= 50% decrease in SPD of nodules; no increase in size of liver or spleen. For bone marrow: irrelevant if positive prior to therapy. SD is failure to attain CR/PR or PD.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Control Rate for Part A
Percentage of participantsPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kg
Percentage of Participants With Disease Control Rate for Part A66.7 (9.4 to 99.2)50.0 (6.8 to 93.2)66.7 (9.4 to 99.2)80.0 (28.4 to 99.5)66.7 (9.4 to 99.2)73.6 (61.9 to 83.3)
SecondaryDuration of Disease Control for Part A

Duration of disease control is defined as the time period from start of MEDI-551 administration to the event of PD/relapse according to IWG criteria. PD is defined as any new lesion or increase by \>=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion(s) \> 1.5 cm in any axis, \>= 50% increase in SPD of more than one node, or \>= 50% increase in longest diameter of a previously identified node \> 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: \> 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate duration of disease control.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Median · Months
Duration of Disease Control for Part A
MonthsPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kg
Duration of Disease Control for Part A12.6 (1.4 to 12.6)NA (9.4 to 21.0)NA (3.5 to 7.4)10.9 (3.9 to 94.9)6.6 (2.8 to 6.6)18.0 (0.9 to 49.7)
SecondaryTime to Response for Part A

The TTR is measured from the start of MEDI-551 administration to the first documentation of response (CR or PR) and assessed in participants who have achieved objective response. Kaplan-Meier method was used to evaluate TTR.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Median · Months
Time to Response for Part A
MonthsPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kg
Time to Response for Part A3.7 (3.5 to 3.9)——1.9 (1.9 to 1.9)3.6 (3.6 to 3.6)3.2 (0.3 to 22.6)
SecondaryProgression Free Survival for Part A

The PFS is measured from the start of MEDI-551 treatment until the first documentation of disease progression, relapse or death, whichever occurs first. Kaplan-Meier method was used to evaluate PFS. The PFS was censored on the date of last disease assessment for participants who have no documented PD/relapse or death prior to data cutoff, dropout, or the initiation of alternative anticancer therapy.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Median · Months
Progression Free Survival for Part A
MonthsPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kg
Progression Free Survival for Part A12.6 (1.4 to 12.6)5.9 (0.6 to 21.0)3.5 (1.6 to 9.9)4.9 (1.1 to 94.9)6.6 (2.1 to 6.6)11.3 (0.0 to 49.7)
SecondaryOverall Survival for Part A

The OS is measured from the start of MEDI-551 treatment until death. For participants who are alive at the end of study or lost to follow-up, OS will be censored on the last date when participants were known to be alive. Kaplan-Meier method was used to evaluate OS.

Time frame:
Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Reported as:
Median · Months
Overall Survival for Part A
MonthsPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kg
Overall Survival for Part ANA (1.4 to 21.5)44.6 (0.8 to 91.5)9.9 (2.8 to 9.9)NA (1.7 to 94.9)8.1 (2.8 to 12.5)45.3 (0.7 to 83.5)
SecondaryTrough Serum Concentration of MEDI-551 by Treatment Cycle

Trough serum concentration (Ctrough) is defined as lowest concentration reached by a drug before the next dose is administered. The Ctrough concentration of MEDI-551 by treatment cycle is reported.

Time frame:
For Part A: C1D1 of each cycles; For Part B: C1D1 of each cycle + C1D8, C1D15, and C1D22; For Part C: C1D2, C1D8, then Day 1 of each cycle until Cycle 10;For Part D: C1D1, C1D8, then Day 1 of each cycle until Cycle 10
Reported as:
Mean · μg/mL
Trough Serum Concentration of MEDI-551 by Treatment Cycle
μg/mLPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart A-MEDI-551 12 mg/kg (Expansion)Part B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
Cycle 1 (C1) Day 1 (D1)NA ± NA0.333 ± 0.665NA ± NANA ± NANA ± NANA ± NA2.97 ± 24.1NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
C1D2NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
C1D8NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA46.5 ± 20.9102 ± 25.0125 ± NA58.0 ± 14.3115 ± 38.0109 ± 58.5
C1D15NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA81.8 ± 38.3197 ± 51.2329 ± NANA ± NANA ± NANA ± NA
C1D22NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA116 ± 47.4281 ± 29.5—NA ± NANA ± NANA ± NA
C2D115.6 ± 0.82325.9 ± 10.912.9 ± 4.5559.4 ± 11.089.8 ± 64.9166 ± 54.0124 ± 64.8122 ± 37.2326 ± 68.0—52.4 ± 17.7106 ± 28.8114 ± 40.1
C3D119.3 ± 3.3326.9 ± 12.26.78 ± 2.0143.0 ± 8.4097.0 ± 94.5149 ± 46.2113 ± 70.357.6 ± 43.1187 ± 80.6—44.7 ± 14.292.1 ± 30.793.9 ± 35.6
C4D120.9 ± 6.6936.5 ± 0.5505.59 ± 0.14637.9 ± 13.833.4 ± NA146 ± 55.5113 ± 57.136.0 ± 31.6134 ± 67.7—48.2 ± 20.8113 ± 70.0102 ± 61.5
C5D126.6 ± 7.1746.8 ± 8.03—56.9 ± 19.631.8 ± NA136 ± 19.3117 ± 60.935.7 ± 32.0121 ± 78.1—51.6 ± 2.64102 ± 26.3147 ± 105
C6D129.1 ± 6.1729.1 ± 17.311.7 ± NA32.0 ± NA33.7 ± NA138 ± 27.2123 ± 67.937.3 ± 33.5106 ± 54.6—45.9 ± NA100 ± 22.9150 ± 116
C7D131.4 ± 7.0825.1 ± 27.89.93 ± NA38.2 ± NA27.9 ± NA144 ± 42.4109 ± 64.228.1 ± 21.295.1 ± 54.4—45.3 ± NA108 ± 20.2248 ± NA
C8D127.1 ± 14.928.0 ± 1.868.80 ± NA33.3 ± NA—109 ± NA114 ± 63.830.8 ± 30.486.8 ± 54.4——147 ± 82.2177 ± NA
C9D121.6 ± NA31.6 ± 1.2310.7 ± NA33.6 ± NA—124 ± 23.2121 ± 77.527.3 ± 27.194.8 ± 69.4——95.0 ± 7.59192 ± 25.9
C10D117.6 ± NA25.1 ± NA10.6 ± NA32.9 ± NA—98.3 ± 5.05139 ± 80.433.4 ± 34.884.2 ± 57.4——113 ± 27.6215 ± NA
SecondaryPeak Serum Concentration of MEDI-551 by Treatment Cycle

Peak serum concentration is concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and before the administration of a second dose.

Time frame:
For Part A: C1D1 of each cycles; For Part B: C1D1 of each cycle + C1D8, C1D15, and C1D22; For Part C: C1D2, C1D8, then Day 1 of each cycle until Cycle 10;For Part D: C1D1, C1D8, then Day 1 of each cycle until Cycle 10
Reported as:
Mean · μg/mL
Peak Serum Concentration of MEDI-551 by Treatment Cycle
μg/mLPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart A-MEDI-551 12 mg/kg (Expansion)Part B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
Cycle 1 (C1) Day 1 (D1)12.3 ± 1.2022.8 ± 1.2446.0 ± 22.2100 ± 11.0166 ± 59.5280 ± 99.1240 ± 90.0122 ± 24.2335 ± 79.1199 ± NANA ± NANA ± NA260 ± 87.3
C1D2NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA160 ± 23.5214 ± 79.9NA ± NA
C1D8NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA162 ± 17.3393 ± 80.8470 ± NA246 ± 76.1115 ± 38.0303 ± 97.4
C1D15NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA182 ± 31.1517 ± 135619 ± NANA ± NANA ± NANA ± NA
C1D22NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA208 ± 46.7533 ± 223—NA ± NANA ± NANA ± NA
C2D127.5 ± 0.75243.9 ± 13.248.8 ± 21.7149 ± 29.7238 ± 106467 ± 114350 ± 130186 ± 116749 ± 133—205 ± 33.5304 ± 108333 ± 72.7
C3D126.3 ± 2.2046.4 ± 16.658.7 ± 0.783145 ± 31.2260 ± 89.6374 ± 116326 ± 110155 ± 38.2374 ± 125—192 ± 78.1311 ± 74.0277 ± 95.7
C4D130.3 ± 5.4648.3 ± 12.763.7 ± 35.1161 ± 85.6201 ± NA359 ± 115342 ± 119156 ± 81.7384 ± 169—212 ± 84.1261 ± 99.4295 ± 116
C5D139.4 ± 6.8570.8 ± 5.43—151 ± 58.1203 ± NA372 ± 113347 ± 98.1153 ± 71.6363 ± 261—250 ± 82.3290 ± 66.0338 ± 245
C6D140.4 ± 3.8734.4 ± 4.2143.2 ± NA123 ± NA198 ± NA345 ± 101337 ± 82.1130 ± 45.7349 ± 140—209 ± NA332 ± 102303 ± 237
C7D141.3 ± 4.7239.5 ± 30.841.0 ± NA123 ± NA182 ± NA383 ± 54.6355 ± 95.7174 ± 60.4333 ± 133—235 ± NA392 ± 93.0502 ± NA
C8D129.9 ± 12.358.2 ± 16.932.2 ± NA130 ± NA—409 ± NA367 ± 102164 ± 52.0342 ± 173——317 ± 150511 ± NA
C9D132.2 ± NA46.8 ± 5.5837.8 ± NA127 ± NA—391 ± 79.6394 ± 125159 ± 64.7299 ± 69.8——363 ± 90.3593 ± 200
C10D143.3 ± NA33.5 ± NA42.3 ± NA133 ± NA—307 ± 49.8394 ± 157166 ± 64.1316 ± 189——349 ± 70.4484 ± NA
SecondaryArea Under the Concentration Curve at Steady State (AUCss) of MEDI-551

Area under the concentration-time curve at steady state (Css, AUC) of MEDI-551 is reported.

Time frame:
Part A:Cycle(C)1 Day(D)1 (Pre & post dose [PPD] 2,6,24,48 hrs PD); PPD once a week in 4 weeks C till C71; Part B:C1 (D1,D8,D15,D22),PPD of D1 of each C till C28; Part C & D:PPD of C1 (D2,D8), predose D15 and 22, PPD of D1 of each C till C24
Reported as:
Mean · μg⋅day/mL
Area Under the Concentration Curve at Steady State (AUCss) of MEDI-551
μg⋅day/mLPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart A-MEDI-551 12 mg/kg (Expansion)Part B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
Area Under the Concentration Curve at Steady State (AUCss) of MEDI-551212 ± 28.1287 ± 110479 ± 57.71660 ± 7782880 ± 21905720 ± 16204850 ± 17201730 ± 10304920 ± 1440NA ± NA2240 ± 3384260 ± 13404250 ± 2000
SecondaryApparent Clearance of MEDI-551

Apparent clearance of MEDI-551 is reported.

Time frame:
Part A:Cycle(C)1 Day(D)1 (Pre & post dose [PPD] 2,6,24,48 hrs PD); PPD once a week in 4 weeks C till C71; Part B:C1 (D1,D8,D15,D22),PPD of D1 of each C till C28; Part C & D:PPD of C1 (D2,D8), predose D15 and 22, PPD of D1 of each C till C24
Reported as:
Mean · mL/day
Apparent Clearance of MEDI-551
mL/dayPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart A-MEDI-551 12 mg/kg (Expansion)Part B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
Apparent Clearance of MEDI-551206 ± 101302 ± 173373 ± 70.9210 ± 28.9268 ± 126198 ± 44.3235 ± 110303 ± 108243 ± 81.6279 ± NA288 ± 43.0235 ± 87.5237 ± 72.5
SecondaryVolume of Distribution of MEDI-551

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Central volume of distribution (Vd1) is defined as hypothetical volume into which a drug initially distributes upon administration and peripheral volume of distribution (Vd2) is defined as the sum of all tissue spaces outside the central compartment.

Time frame:
Part A:Cycle(C)1 Day(D)1 (Pre & post dose [PPD] 2,6,24,48 hrs PD); PPD once a week in 4 weeks C till C71; Part B:C1 (D1,D8,D15,D22),PPD of D1 of each C till C28; Part C & D:PPD of C1 (D2,D8), predose D15 and 22, PPD of D1 of each C till C24
Reported as:
Mean · mL
Volume of Distribution of MEDI-551
mLPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart A-MEDI-551 12 mg/kg (Expansion)Part B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
Vd13970 ± 8513920 ± 4914350 ± 9484070 ± 4644210 ± 5104230 ± 2344450 ± 8893560 ± 2864490 ± 9475690 ± NA4520 ± 1264350 ± 8514510 ± 647
Vd22670 ± 3512010 ± 10801980 ± 8882290 ± 7672620 ± 12402920 ± 10703430 ± 22503290 ± 14402640 ± 18403670 ± NA4590 ± 8472640 ± 12003200 ± 1440
SecondaryTerminal Half-life (t1/2) of MEDI-551

Terminal half-life is the time required for the plasma concentration of MEDI-551 to fall by 50% during the terminal phase.

Time frame:
Part A:Cycle(C)1 Day(D)1 (Pre & post dose [PPD] 2,6,24,48 hrs PD); PPD once a week in 4 weeks C till C71; Part B:C1 (D1,D8,D15,D22),PPD of D1 of each C till C28; Part C & D:PPD of C1 (D2,D8), predose D15 and 22, PPD of D1 of each C till C24
Reported as:
Mean · Days
Terminal Half-life (t1/2) of MEDI-551
DaysPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart A-MEDI-551 12 mg/kg (Expansion)Part B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
Terminal Half-life (t1/2) of MEDI-55126.0 ± 6.8817.3 ± 7.6513.3 ± 6.4122.1 ± 3.2621.7 ± 8.6527.9 ± 9.0828.9 ± 15.019.9 ± 9.3423.8 ± 10.925.1 ± NA25.3 ± 4.4023.6 ± 9.3825.6 ± 7.96
SecondaryNumber of Participants With Positive Anti-drug Antibodies (ADA) Titer to MEDI-551

Number of participants with positive Anti-drug antibodies (ADA) titer to MEDI-551 is reported.

Time frame:
Part A:C1D1; Part B: C1D1; Part C: C1D1; Part D: C1D1; End of treatment (EOT); 90 Days post last dose (approximately 9 years)
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-drug Antibodies (ADA) Titer to MEDI-551
ParticipantsPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
C1D101000200002
EOT00000000000
90 Day Post Dose00000000000
SecondaryB-cell Concentration in Serum

B-cell Concentration in serum is reported.

Time frame:
Part A:C1D1 of each cycles; Part B: C1D1 of each cycle + C1D8, C1D15, and C1D22; Part C: C1D2, C1D8, then Day 1 of each cycle until Cycle 10; Part D: C1D1, C1D8, Day 1 of each cycle until Cycle 10; EOT;90 Days post last dose (approximately 9 years)

No measurements were reported for this outcome.

SecondaryImmunoglobulin (Ig) Concentration in Serum

Immunoglobin (Ig) concentration in serum is reported.

Time frame:
Part A:C1D1 of each cycles; EOT;90 Days post last dose (approximately 9 years)
Reported as:
Mean · mg/dL
Immunoglobulin (Ig) Concentration in Serum
mg/dLPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kg
C1D1120.00 ± 46.36110.00 ± 76.2581.00 ± 66.3661.67 ± 54.5293.33 ± 46.1193.01 ± 88.56
C2D167.50 ± 7.78113.67 ± 92.8167.67 ± 58.0557.00 ± 47.0574.50 ± 47.3888.90 ± 92.05
C3D162.50 ± 6.36106.00 ± 87.9331.00 ± 29.7057.25 ± 48.2976.50 ± 50.2067.90 ± 66.59
C4D164.00 ± 9.90152.50 ± 13.4431.00 ± 33.9463.67 ± 56.5298.00 ± NA66.84 ± 61.83
C5D169.00 ± 11.31145.50 ± 38.8950.00 ± NA58.67 ± 45.1777.00 ± NA69.24 ± 70.45
C6D163.50 ± 13.44156.00 ± 48.08—41.00 ± NA71.00 ± NA62.86 ± 65.04
C7D156.00 ± 1.41127.00 ± NA47.00 ± NA41.00 ± NA61.00 ± NA67.26 ± 69.36
C8D147.00 ± 7.07147.00 ± 28.2845.00 ± NA41.00 ± NA—73.76 ± 66.87
C9D151.00 ± NA137.50 ± 30.4146.00 ± NA41.00 ± NA—62.35 ± 61.90
C10D147.00 ± NA155.00 ± NA46.00 ± NA41.00 ± NA—73.17 ± 66.34
EOT43.50 ± 12.0296.00 ± 80.587.00 ± NA54.40 ± 46.5565.33 ± 19.76217.25 ± 1003.38
90 Days Post Dose49.00 ± NA84.50 ± 60.10—93.33 ± 42.06—45.20 ± 38.72

Adverse events

Collected over Day 1 through 90-Day Post Last Dose (Approximately 9 years). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A-MEDI-551 0.5 mg/kg0/3 (0%)1/3 (33.3%)3/3 (100%)
Part A-MEDI-551 1 mg/kg2/4 (50%)1/4 (25%)4/4 (100%)
Part A-MEDI-551 2 mg/kg2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Part A-MEDI-551 4 mg/kg1/6 (16.7%)1/6 (16.7%)6/6 (100%)
Part A-MEDI-551 8 mg/kg2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Part A-MEDI-551 12 mg/kg30/76 (39.5%)23/76 (30.3%)75/76 (98.7%)
Part B-MEDI-551 6 mg/kg1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Part B-MEDI-551 12 mg/kg0/3 (0%)2/3 (66.7%)3/3 (100%)
Part B-MEDI-551 24 mg/kg1/1 (100%)1/1 (100%)1/1 (100%)
Part C-MEDI-551 8 mg/kg + Rituximab2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Part C-MEDI-551 12 mg/kg + Rituximab9/17 (52.9%)9/17 (52.9%)17/17 (100%)
Part D-MEDI-551 12 mg/kg8/14 (57.1%)5/14 (35.7%)14/14 (100%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/30/40/30/60/30/760/30/31/10/30/170/14
Deep vein thrombosisVascular disorders0/30/40/30/60/30/760/30/31/10/30/170/14
Febrile neutropeniaBlood and lymphatic system disorders0/30/40/30/60/31/760/31/30/10/31/170/14
PancreatitisGastrointestinal disorders0/30/40/30/60/30/760/31/30/10/30/170/14
CholecystitisHepatobiliary disorders0/30/40/30/60/30/760/31/30/10/30/170/14
BronchitisInfections and infestations0/30/40/30/60/30/760/31/30/10/31/171/14
GastroenteritisInfections and infestations0/30/40/30/60/31/761/30/30/10/30/170/14
PneumoniaInfections and infestations0/30/40/31/60/32/760/31/30/10/31/172/14
VaricellaInfections and infestations0/30/40/30/60/30/760/31/30/10/30/170/14
Back painMusculoskeletal and connective tissue disorders1/30/40/30/60/31/760/30/30/10/30/170/14
Most frequent other events
Showing 10 of 330
Most frequent other events
EventPart A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kg
AnaemiaBlood and lymphatic system disorders0/32/40/30/61/36/760/31/31/10/34/172/14
Vision blurredEye disorders0/30/40/30/60/32/760/30/31/10/30/170/14
DiarrhoeaGastrointestinal disorders3/32/41/30/60/318/761/32/31/11/35/173/14
Dry mouthGastrointestinal disorders0/30/40/30/60/32/760/30/31/10/31/171/14
FatigueGeneral disorders1/31/41/32/63/328/762/33/30/11/39/175/14
Oedema peripheralGeneral disorders0/31/40/30/60/38/760/32/31/10/35/172/14
ContusionInjury, poisoning and procedural complications0/30/41/31/60/32/760/30/31/10/32/170/14
FallInjury, poisoning and procedural complications0/30/40/30/60/30/760/30/31/10/31/171/14
Infusion related reactionInjury, poisoning and procedural complications0/30/40/32/60/334/761/32/31/10/31/174/14
Rib fractureInjury, poisoning and procedural complications0/30/40/30/60/30/760/30/31/10/30/170/14

Baseline characteristics

Safety population included all participants who received any treatment of MEDI-551.

Age, Continuous
Age, Continuous(Years)Part A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kgTOTAL
Mean66.0 ± 19.569.5 ± 12.564.7 ± 18.363.8 ± 12.760.0 ± 12.164.4 ± 11.261.3 ± 20.870.0 ± 7.078.0 ± NA68.0 ± 11.869.4 ± 10.867.9 ± 11.065.7 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Part A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kgTOTAL
Female2012130111110555
Male142424622027981
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kgTOTAL
Hispanic or Latino0000060000006
Not Hispanic or Latino343637033131714130
Unknown or Not Reported0000000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A-MEDI-551 0.5 mg/kgPart A-MEDI-551 1 mg/kgPart A-MEDI-551 2 mg/kgPart A-MEDI-551 4 mg/kgPart A-MEDI-551 8 mg/kgPart A-MEDI-551 12 mg/kgPart B-MEDI-551 6 mg/kgPart B-MEDI-551 12 mg/kgPart B-MEDI-551 24 mg/kgPart C-MEDI-551 8 mg/kg + RituximabPart C-MEDI-551 12 mg/kg + RituximabPart D-MEDI-551 12 mg/kgTOTAL
American Indian or Alaska Native0000000000000
Asian0000000000101
Native Hawaiian or Other Pacific Islander0000000000000
Black or African American0101050100008
White333536832121514122
More than one race0000000000000
Unknown or Not Reported0000030001105
08

Study locations

21 sites
  • Research Site
    Birmingham, Alabama 35249, United States
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    Washington, District of Columbia 20007, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Westwood, Kansas 66205, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    New Brunswick, New Jersey 08903, United States
  • Research Site
    Lake Success, New York 11042, United States
  • Research Site
    Hershey, Pennsylvania 17033, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Morgantown, West Virginia 26506, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Yvoir, 5530, Belgium
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Cona, 44124, Italy
  • Research Site
    Modena, 41124, Italy
  • Research Site
    Madrid, 28033, Spain
  • Research Site
    Madrid, 28050, Spain
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2010 to primary completion in Mar 2019, 107 months.

Results were first posted in May 2020, 1 year 1 month after primary completion.

Of 195 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 107 months is above that.

Counting every sponsor, half of 297 studies reached it within 60 months; a quarter within 39 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2009
First posted
Sep 24, 2009
StartActual
Apr 16, 2010
Primary completionActual
Mar 21, 2019
CompletionActual
Mar 21, 2019
Results first posted
May 13, 2020
Last update
May 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00983619
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Sep 24, 2009
Start date
Apr 16, 2010
Primary completion
Mar 21, 2019
Completion
Mar 21, 2019
Results posted
May 13, 2020
Last update
May 13, 2020

Study contacts

Medimmune Inc. Clinical Development
study director · MedImmune LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inebilizumab

Start the discussion